(Q24240929)

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Viral factors associated with cytokine expression during HCV/HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Interferon‐Ribavirin in Association with Stavudine Has No Impact on Plasma Human Immunodeficiency Virus (HIV) Type 1 Level in Patients Coinfected with HIV and Hepatitis C Virus: A CORIST‐ANRS HC1 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Hepatic steatosis in HIV–HCV coinfected patients: analysis of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Rapid and early virological response to chronic hepatitis C treatment with IFN 2b or PEG-IFN 2b plus ribavirin in HIV/HCV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Pilot study of interferon-alpha with and without amantadine for the treatment of hepatitis C in HIV coinfected individuals on antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Ribavirin plus interferon versus interferon for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Bias in clinical intervention research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Hepatitis C and HIV-1 coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Interferon for interferon naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

HIV and hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Management of hepatitis C in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Coinfection with HIV and HCV: more questions than answers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

American Gastroenterological Association medical position statement on the management of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004888.PUB2